FDA Updates Abacavir and Lamivudine Labeling

"On March 23, 2015, FDA approved revisions to the Epivir (lamivudine) and Ziagen (abacavir sulfate) labels to each provide for once-daily dosing in pediatric patients 3 months of age and older in combination with other antiretroviral agents for the treatment of HIV-1 infection."   The updated labeling for both drugs will be available soon at the FDA website.   More information is available:  FDA: Press release AIDSinfo: Patient fact sheet on abacavir AIDSinfo: Patient fact sheet on lamivudine